Publications

A dominance approach to analyze the incidence of catastrophic health expenditures in Iran.

Hsu, J; Majdzadeh, R; MILLS, A; HANSON, K;

2021

Social science & medicine (1982), (2021).285, 10.1016/j.socscimed.2021.114022.

Effectiveness and cost-effectiveness of integrating the management of depression into routine HIV Care in Uganda (the HIV + D trial): A protocol for a cluster-randomised trial.

KINYANDA, E; Kyohangirwe, L; Mpango, RS; Tusiime, C; Ssebunnya, J; KATUMBA, K; Tenywa, P; Mugisha, J; Taasi, G; Sentongo, H; Akena, D; LAURENCE, Y; Muhwezi, W; WEISS, HA; NEUMAN, M; GRECO, G; Knizek, B; Levin, J; KALEEBU, P; Araya, R; Ssembajjwe, W; Patel, V;

2021

International journal of mental health systems, (2021).15 1 10.1186/s13033-021-00469-9.

Can Results-Based Financing improve health outcomes in resource poor settings? Evidence from Zimbabwe.

Fichera, E; Anselmi, L; Gwati, G; Brown, G; Kovacs, R; BORGHI, J;

2021

Social Science & Medicine, (2021).279, 10.1016/j.socscimed.2021.113959.

How do healthcare providers respond to multiple funding flows? A conceptual framework and options to align them.

Barasa, E; Mathauer, I; Kabia, E; Ezumah, N; Mbau, R; Honda, A; Dkhimi, F; Onwujekwe, O; Phuong, HT; HANSON, K;

2021

Health policy and planning, (2021).36 6 10.1093/heapol/czab003.

Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses.

Nymark, LS; Miller, A; VASSALL, A;

2021

PharmacoEconomics - open, (2021).5 4 10.1007/s41669-021-00269-4.

Evaluation of a Novel Culture System for Rapid Pathogen Identification and Detection of Cephalosporin Resistance in Neonatal Gram-negative Sepsis at a Tertiary Referral Unit in Harare, Zimbabwe.

Chimhini, G; OLARU, ID; Fitzgerald, F; Chisenga, M; Ferreyra, C; Malou, N; Piton, J; Chimhuya, S; YEUNG, S; De, S; Mujuru, HA; KRANZER, K;

2021

The Pediatric infectious disease journal, (2021).40 9 10.1097/INF.0000000000003155.

A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN.

Willigers, B; Ouwens, M; BRIGGS, A; Darlington, O; Bhatt, P; Wittbrodt, E; Sinsakul, M; Heerspink, HL; Pollock, C; Filho, RF S P; Tangri, N; Kovesdy, C; Wheeler, D; Sanchez, JJ G;

2021

NEPHROLOGY DIALYSIS TRANSPLANTATION, (2021).36,

Global economic productivity losses from vision impairment and blindness.

MARQUES, AP; RAMKE, J; CAIRNS, J; Butt, T; Zhang, JH; Muirhead, D; Jones, I; Tong, BA M A; Swenor, BK; Faal, H; Bourne, RR A; Frick, KD; BURTON, MJ;

2021

EClinicalMedicine, (2021).35, 10.1016/j.eclinm.2021.100852.

Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries.

NEMZOFF, C; RUIZ, F; Chalkidou, K; Mehndiratta, A; GUINNESS, L; Cluzeau, F; Shah, H;

2021

BMJ GLOBAL HEALTH, (2021).6 4 10.1136/bmjgh-2020-004549.

Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study.

Tildesley, MJ; VASSALL, A; Riley, S; JIT, M; SANDMANN, F; Hill, EM; Thompson, RN; Atkins, BD; EDMUNDS, J; Dyson, L; Keeling, MJ;